Therapeutic liver cell transplantation to treat murine PKU
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Melanie Willimann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Phenylketonurias, Hepatocytes, Disease Models, Animal, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
For gene therapy of the liver, in vivo applications based on adeno‐associated virus are the most advanced vectors despite limitations, including low efficacy and episomal loss, potential integration and safety issues, and high production costs. Alternative vectors and/or delivery routes are of high interest. The regenerative ability of the liver bears the potential for ex vivo therapy using liver cell transplantation for disease correction if provided with a selective advantage to expand and replace the existing cell mass. Here we present such treatment of a mouse model of human phenylketonuria (PKU). Primary hepatocytes from wild‐type mice were gene modified in vitro (with a lentiviral vector) that carries a gene editing system (CRISPR) to inhibit Cypor . Cypor inactivation confers paracetamol (or acetaminophen) resistance to hepatocytes and thus a growth advantage to eliminate the pre‐existing liver cells upon grafting (via the spleen) and exposure to repeated treatment with paracetamol. Grafting Cypor ‐inactivated wild‐type hepatocytes into inbred young adult enu2 (PKU) mice, followed by selective expansion by paracetamol dosing, resulted in replacing up to 5% of cell mass, normalization of blood phenylalanine, and permanent correction of PKU. Hepatocyte transplantation offers thus an armamentarium of novel therapy options for genetic liver defects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
- University of Zurich, Institute for Pharmacology and Toxicology, Zurich, Switzerland.
ORCID-Profile: Gerald Schwank, Beat Thöny
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Willimann, M., Grisch-Chan, H. M., Rimann, N., Rothgangl, T., Hruzova, M., Schwank, G., & Thöny, B. (2024). Therapeutic liver cell transplantation to treat murine PKU. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12802
Vancouver
Willimann M, Grisch-Chan HM, Rimann N, Rothgangl T, Hruzova M, Schwank G, et al. Therapeutic liver cell transplantation to treat murine PKU. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12802
BibTeX
@article{Willimann2024,
author = {Willimann, Melanie and Grisch-Chan, Hiu Man and Rimann, Nicole and Rothgangl, Tanja and Hruzova, Martina and Schwank, Gerald and Thöny, Beat},
title = {Therapeutic liver cell transplantation to treat murine PKU},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12802}
}
EUVIMED